Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model

Table 4 Projected health outcomes by vaccination strategy for children <10 years old

Health Outcome*	PCV-7 vaccination	PHiD-CV vs PCV-7	PCV-13 vs PCV-7	PHiD-CV vs PCV-13
IPD cases	1,991	−190	−225	34
Pneumonia hospitalizations	7,686	−323	−361	38
AOM hospitalizations	24,894	−8,956	−2,234	−5,722
AOM GP visits	2,930,976	−267,212	−75,019	−192,193
Total LYs	1,065,775,026	−2,081	−2,146	65
Total QALYs	906,683,318	−3,156	−2,223	−933

*Negative numbers represents cases/QALYs/LYs in favor of first comparator.
AOM acute otitis media, GP general practitioner, IPD invasive pneumococcal disease, LY life year, PCV-7 7-valent pneumococcal conjugate vaccine, PCV-13 13-valent pneumococcal conjugate vaccine, PHiD-CV pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine, QALY quality-adjusted life year.

ISSN: 1472-6963